Ohio State Cancer Expert Receives NCI Award For Team Leadership

November 02, 2011
Ohio State Cancer Expert Receives NCI Award For Team Leadership Bekiai Saab

COLUMBUS, Ohio – Dr. Tanios Bekaii-Saab, medical director of gastrointestinal oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), is one of 11 physicians nationwide selected to receive the National Cancer Institute (NCI)'s Clinical Investigator Team Leadership Award.

The award, funded by the NCI is designed to provide recognition and funding for clinical investigators at NCI-designated cancer centers who are participating extensively in NCI-funded collaborative clinical trials.

The 11 clinical investigators are being recognized for their exceptional contributions to the advancement of new therapies by establishing effective collaborations with other scientists through their team science approach within NCI-funded clinical trials. The two-year award provides investigators with $50,000 annually for their leadership roles in clinical trials at NCI-designated cancer centers.

Bekaii-Saab specializes in the development of experimental agents for gastrointestinal malignancies including pancreatic, liver and colon cancers. As an associate professor of Medicine at the OSUCCC-James and of pharmacology at Ohio State's College of Medicine, he is the leader of the disease specific research group for gastrointestinal oncology.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News & World Report.

###

Contact: Gretchen Sauer, Medical Center Public Affairs and Media Relations, 614-293-3737, or Gretchen.Sauer@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations


614-685-5420 (direct)


614-293-3737 (main)


Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

A New Approach to Cervical-Cancer Prevention

With its Pelotonia idea grant, a team of OSUCCC – James researchers is developing and pilot testing an HPV self-testing program.

Cell Therapy Offers New Way to Treat Certain Cancers

The research and medical experts at The James are using something called cell therapy to treat some cancers as well as find new ways treat others.

CanDL Database Shines Light on Clinically Important Cancer Gene Mutations

To help molecular pathologists, laboratory directors, bioinformaticians and oncologists identify key mutations that drive tumor growth in tissues obtained during clinical studies, researchers at the...